UNIVERSAL-WELLNESS-LABS
5.5.2021 14:21:06 CEST | Business Wire | Press release
Digital Health Certificates are happening. Governments, airlines and the industry at large need solutions to get the people moving freely and safely. Universal Wellness Labs creates a wearable for hand cleaning that holds the QR-code for Health Certificates. The user-friendly gadget serves as an alternative medium, and as a back-up for the QR-codes in smartphone apps or printed on paper.
Health Certificates, a.k.a. Immunity Passports, Vaccine Certificates, Green Passes and PCR tests come as QR-code for storage in apps in people’s smartphones or printed on paper.
Universal Wellness Labs foresees potential issues and uses NFC as a medium for the QR.
It pairs the Health Certificate with hand hygiene in one useful and user-friendly wearable dispenser for hand sanitizer: the Zpritzi.
Marinus Vander Slikke, CEO of Universal Wellness Labs: “A document as vital as a Health Certificate must have a back-up. Apps can crash. Smartphones can die. Paper-printed QR-codes are old world, prone to forgery and get lost easily.”
NFC is secure, contactless and works without electronics and networks.
A video-presentation of the Zpritzi concept is available at www.zpritzi.com .
Universal Wellness Labs recently presented its concept to the European Commission.
Marinus Vander Slikke: “We anticipate deeper negotiations soon. Sweden and Denmark have already endorsed NFC. However, we are also targeting the private sector like airlines, hotels, cruise ships and event organisers.”
Zpritzi is a slim, elongated and ergonomic designed wearable gadget. Made from recyclable ABS. Refillable with any sanitizer spray. An integrated encrypted NFC tag stores the QR-code. People wear it around their neck, or on their belt or hand-bag.
Zpritzi is low-cost and an ideal product for corporate branding: It verifies people’s health status, makes hand disinfection easy and is a promotional tool with lasting marketing effects.
A pilot study with 88 participants shows the efficacy of the Zpritzi. Users clean their hands 75% more often with a Zpritzi than with conventional portable bottles.
Marinus Vander Slikke: “Hand cleaning is a first line of defence against any kind of bacteria and viruses, including Covid. Both the public and the private sector require proof of health to enter their country or premises. A quick scan of the Zpritzi verifies people’s health status. And the big advantage is that people always go in with clean hands.”
“In the new normal people still want to be trendy and look smart. Similar to face masks, Zpritzi makes the Health Certificate and hand sanitizing cool.”
Zpritzi is created in cooperation with Design2Gather, an award winning Dutch design company (design2gather.com ).
Universal Wellness Labs OÜ is an Estonia based company that conceptualizes and designs products for personal health and wellness (universalwellnesslabs.com ).
###
View source version on businesswire.com: https://www.businesswire.com/news/home/20210505005604/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom